| Northern California Cornea Associates.inc. | |
|
491 30th St., Suite 101, Oakland, CA 94609-3052 | |
| (510) 444-0603 | |
| (510) 444-6046 |
| Full Name | Northern California Cornea Associates.inc. |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 491 30th St., Oakland, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063542777 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Northern California Cornea Associates.inc. 491 30th St., Suite 101, Oakland, CA 94609-3235 Ph: (510) 444-0603 | Northern California Cornea Associates.inc. 491 30th St., Suite 101, Oakland, CA 94609-3052 Ph: (510) 444-0603 |
News Archive
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson's raloxifene hydrochloride tablet is a generic version of Eli Lilly's EVISTA®.
Cell phones have become our constant companions, and as a result, they are exposed to many bacteria and viruses. When we open a door, shake hands, use an ATM or dozens of other daily tasks, our hands come in contact with germs, and numerous studies have shown that a significant number of bacteria, such as the flu virus, staph, strep, E. coli, and salmonella, are transferred from our hands to our cell phones every time we pick them up.
Acute foodborne illnesses cost the United States an estimated $152 billion per year in healthcare, workplace and other economic losses, according to a report published today by the Produce Safety Project (PSP).
Rules-Based Medicine, Inc. (RBM) today announced that Psynova Neurotech Limited (Cambridge UK), a majority-owned subsidiary of RBM, has executed an exclusive research and licensing agreement with Roche to collaborate on the discovery, development, validation and commercialization of diagnostic immunoassays to aid the clinical development and commercial differentiation of novel treatments for schizophrenia.
Calculations by researchers at the University of California, San Francisco and the University of California, Berkeley estimate that the cancer risk associated with one type of airport security scanners is low based on the amount of radiation these devices emit, as long as they are operated and function correctly.
› Verified 1 days ago